Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Each year there is an evolution in the way
we approach education and information, each year there are additional
topics…and each year we ensure that we try to respond to what we have
heard from you as we remain open to the challenges and the technical
improvements in our speciality. The EAPCI and EuroPCR believe it is
important to confront the issues, openly and honestly, engaging with new
techniques, teaching the older ones and engaging the younger members of
our speciality through educational programmes and grants.
And this year will be no exception, with
the focus on four tracks –four key topics that are of great interest to
the EAPCI as an association, and to our members. Certain of these topics
are classics, that we have followed since the beginning of EuroPCR; to
these we pay special attention in order to remain on the cutting edge of
knowledge and practice, others are relatively new –such as our
increasing interest in the treatment of resistant hypertension– linked
to emerging data supporting an interventional approach in the treatment
of this condition.
This year, these four main sections are:
“Coronary interventions”; “Interventions for structural heart disease”;
“Endovascular/Peripheral interventions” and “Interventions for
hypertension and heart failure”. While these tracks are inter-related,
there are many new and innovative features specific to each one:
– In “Coronary Interventions” this
year we will be focusing on bioresorbable scaffolds, a technology whose
potential will be fully explored during the Great Debate. Also during
the Great Debate, we will focus on the problems of dual antiplatelet
therapy with the integration of the latest antiplatelet agents. A sample
of other important issues in Coronary this year will be: CTO
interventions, bifurcations and left main management of STEMI with
cardiogenic shock. Intracoronary imaging technology will also be
examined using new CT evaluation techniques allowing for instantaneous
“live and direct” 3-D reconstruction of the coronary arteries.
– The “Interventions for structural
heart disease” will explore routine procedures using new valves and
devices. New indications will be considered and presentations and
discussion will consider the evolution of indications, with the question
of whether there is a role for TAVI in intermediate risk patients. We
will also be looking at mitral disease and mitral valves, as well as
left atrial appendage closure.
– Since the early days of EuroPCR
there has been a special peripheral programme, but this year “The
Endovascular/Peripheral interventions” programme will be completely
invigorated, with new course directors and a totally new design. By
renewing our energies and outlook in this field we hope to attract a new
generation of interventional cardiologists, radiologists and
– “Interventions for hypertension and
heart failure” is an entirely new topic –the focus of the Great Debate
last year as well as the Resistant Hypertension Course – and will deal
with emerging treatments and data on renal sympathetic denervation.
All these tracks are characterised by a
strong balance between live demonstrations, live in a box, and
interaction with the participants. Hotline sessions, Late Breaking
Trials, academic sessions, all of these serve the purpose of furthering
the education of attendees; all have the intention of answering the
participants needs at every level, whether it is theoretical or
practical, with a strong emphasis –as in all EuroPCRs– on what you can
“take home” when you leave Paris.
Following a tradition we began several
years ago, EuroPCR will be the occasion for our Association to award
five grants to further training and clinical education for fellows. With
the support of industry, who help make these grants a reality, the
successful applicants will have the opportunity of receiving a one-year
training or research grant in a European centre known for its expertise
in a chosen subject or field. This year there will be a similar grant
specifically for women, to encourage greater female participation in
interventional cardiology and the EAPCI.
If we apply an evidenced-based approach to
EuroPCR, we would see that the data speaks for itself; that the
official course of our association, made “by you and for you”, is a
success when measured by the increasing support we are attracting from
our members and interventionalists throughout the world. Your response,
by your increasing participation as individuals and groups, is one of
the most exciting aspects of EuroPCR and guarantees another excellent
As we prepare to go to press a few weeks
before the meeting itself, we can already see that this is a fantastic
year in terms of the number of National Societies and National Working
Groups that will be present, 44 in all; 31 of these will be working
closely with the “How should I treat sessions” (HSIT); and, for the
first time, 24 will be sharing their best educational cases! These
numbers speak for themselves, demonstrating the activity and commitment
of our association at a local and national level.
These numbers also touch upon the heart of
what the EAPCI and EuroPCR are about, constructing a meeting that
responds to the needs, challenges and desires of our participants in
such a way that we advance together, through sharing and interaction.
There will be around 60 hours of live transmissions coming from 16
internationally renowned centres. But the truly fantastic numbers are
your contributions: 963 abstracts submitted and 777 clinical cases
submitted –a number that is growing each year! This is your input, and
EuroPCR has become the natural magnet, the natural forum for exchange –
where we all choose to share what we are doing either in research or in
our cathlabs. It is here at EuroPCR that we can have an honest and true
discussion, whether with one of the best international
interventionalists attending or presenting, or with our industry
partners, or among yourselves.
We have claimed that our meeting, EuroPCR
2013, is constructed “by and for” you the attendee, we say, that this is
not a one-way street…and we have the proof in your response – your
presence at our meetings, your membership in our Association, your work
in furthering your speciality and patient care, and we thank you for
your participation and look forward to seeing you at EuroPCR 2013!
© 2017 European Society of Cardiology. All rights reserved